FDA Inspection finds data integrity issues at dabur plant
Synopsis
An FDA inspection of a Dabur manufacturing facility identified data integrity concerns, contamination observations and oversight deficiencies, resulting in a Form 483. The findings come as regulators continue increasing scrutiny of manufacturing standards, testing practices and quality systems at facilities supplying products to international markets.
FDA inspectors issued a Form 483 to Dabur after identifying data integrity concerns, contamination findings, sanitation deficiencies and quality-control weaknesses at a manufacturing facility supplying regulated markets.
Key Highlights
- FDA issued a Form 483 following inspection observations at a Dabur facility.
- Investigators reported data integrity concerns involving laboratory testing records.
- Contamination was observed despite some tests being recorded as compliant.
- Sanitation deficiencies were identified in storage areas.
- Quality-control authority and management oversight were cited as concerns.
- Dabur reported FY25 revenue of Rs 12,563 crore and net profit of Rs 1,768 crore.
The U.S. Food and Drug Administration (FDA) has issued a Form 483 to Dabur India Ltd. for data integrity concerns, contamination observations and quality-control deficiencies found during a manufacturing inspection.
The inspection report shows that investigators discovered laboratory analysts tampered with the data of the tests. Additionally, FDA noted that some microbiology test results were reported as meeting the limits while inspectors found significant contamination in several samples.
They serve as proof that regulators are increasingly focusing on manufacturing controls and data reliability at manufacturing units that are producing products for export to overseas markets.
Testing Records Draw Regulatory Attention
The FDA inspection was related to the quality of the laboratory testing methods used at the facility.
Inspectors noted inadequate documentation of conditions observed when testing was performed in relation to the samples. Manufacturers use test data to decide whether products are of good quality and fit for use before being released, which makes data integrity a mandatory requirement for Current Good Manufacturing Practice (CGMP) regulations.
The agency also reported sanitation issues such as an unknown black substance present in over 25% of the surfaces in the warehouse areas where raw materials and products are stored.
Oversight Gaps Identified
In addition to laboratory results, FDA noted that quality-control units were poorly empowered in the operations of the facility.
Inspectors also noted that, due to poor management, production records were not sufficiently scrutinised prior to release of batches, which led to concerns about compliance oversight.
A Form 483 is a form that FDA investigators send if they see conditions that could be in violation of FDA requirements. The companies will have 15 business days to respond, providing corrective and preventive measures.
Broader Focus on Manufacturing Compliance
The observations come as health authorities all over the world are stepping up their audit of manufacturing facilities that provide medicines and health products globally.
The FDA's foreign inspection programme states that plants in key pharmaceutical manufacturing areas such as India and China are inspected regularly if products are intended for regulated markets.
In recent years, data integrity and documentation practices have been identified repeatedly as areas of focus for the FDA and the ICH (ICH) industry reports.
Dabur reported consolidated revenue of Rs 12,563 crore and net profit of Rs 1,768 crore for FY2024-25.
FAQs
Q1. Why did the FDA issue a Form 483 to Dabur?
The FDA issued a Form 483 after inspectors reported data integrity concerns, contamination observations and quality-control deficiencies at a Dabur manufacturing facility.
Q2. What did FDA inspectors find during the Dabur inspection?
Inspectors cited testing record irregularities, sanitation shortcomings, contamination observations and weaknesses in management oversight.
Q3. What does an FDA Form 483 mean for a manufacturer?
A Form 483 identifies inspection observations that may not meet regulatory requirements and typically requires a formal corrective response from the company.
Follow Inspirepreneur Magazine for daily global business news.
Pooja Malik is a business journalist with over six years of experience covering startups, entrepreneurship, and emerging trends. She has previously worked with leading media platforms such as YourStory Media and BW BusinessWorld, where she reported on business, policy, and market developments. Currently, she serves as Editor at The Inspirepreneur Magazine, where she writes and edits stories across business, lifestyle, and travel, with a focus on clarity, accuracy, and reader relevance.
You Might Also Like
Coalition Split Leaves Australia’s Liberals Isolated
Cadence Fined $200 Million for Supplying Chips to China Illegally
